F. HOFFMANN-LA ROCHE Ltd, MERCK KGAA and AGILENT TECHNOLOGIES, inc. dominated the Europe q-PCR Reagents Market in 2021

Europe q-PCR Reagents Market is expected to grow with a CAGR of 5.5% in the forecast period of 2022 to 2029. The years considered for the study are as mentioned below.

Access Full Report at @ https://www.databridgemarketresearch.com/reports/europe-q-pcr-reagents-market

Europe Q-PCR reagents market is a highly consolidated market, which includes a specific number of key players as well as local players. The market has witnessed increased strategic developments owing to a favorable market scenario.

The major players dealing in the Europe Q-PCR reagents market are introducing a strong range of product portfolios. This helped companies to maximize sales with an enhanced product portfolio.

F. HOFFMANN-LA ROCHE LTD is the dominating player in this market. Some of the other players include Hollister Incorporated, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc, Biotium, MiRXES Pte Ltd, GeneDireX, Inc, Norgen Biotek Corp, Takara Holdings Inc., Enzo Biochem Inc, Qiagen, PCR Biosystems, Cytek Biosciences, Inc., Quantabio, Merck KgaA, Kaneka Eurogentec S.A, Promega Corporation, Solis BioDyne, Seegene Inc., Sino Biological Inc, Thermo Fisher Scientific Inc, New England Biolabs, YouSeq Ltd, and Bioneer Corporation, among others.

  F. HOFFMANN-LA ROCHE LTD

F. HOFFMANN-LA ROCHE LTD is headquartered in Basel, Switzerland. As Public ownership, it was founded in 1896. The company is engaged in creating innovative medicines and diagnostics tests that help millions of people worldwide. The company has Product categories which are Sample Collection, Nucleic Acid Extraction, PCR, RNA Library Prep, qPCR, Oncology Assays and Bioinformatics, out of which qPCR is market focused product. The company has a wide global presence across North America, South America, Asia-Pacific, Europe, Middle East and Africa.

For Instance,

• In January 2018, F. Hoffmann-La Roche Ltd announced the launch of the Cobas Plasma Separation Card. This new solution is a stable and easy-to-use sample collection device for HIV plasma viral load testing. This has raised their sales and product portfolio.

Merck KGAA

Merck KGAA is headquartered in Darmstadt, Germany, as Public ownership, it was founded in 1891. The company focuses on inventing life and bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. Analytics and Sample Preparation, Biopharmaceutical Manufacturing, Industrial Microbiology, IVD/OEM Materials and Reagents, Life Science Research, Reagents, Chemicals and Labware, Small Molecule Pharmaceuticals and Water Purification, out of which Life Science Research is the market focused category. The company has a wide global presence across Europe, Asia-Pacific, North America, South America, Middle East and Africa.

For Instances,

• In March 2021, Merck KGaA announced a strategic partnership with the Faculty of Mathematics and Natural Sciences, Universitas Indonesia (FMIPA-UI), to establish the first Collaboration Laboratory between the company and the university to advance life science research and innovation development in Indonesia. This has increased the company’s product portfolio and sales
• In July 2020, Merck KGaA announced that they are planning to build a new USD 20.44 million laboratory facility in Buchs, Switzerland, to support the company’s rapidly growing reference materials business. This will increase the company’s production and R&D activity

Agilent Technologies, Inc.

Agilent Technologies, Inc. is headquartered in California, U.S., as Public ownership. It was founded in 1999. The company focuses on providing life sciences, diagnostics and applied chemical markets and also provides laboratories worldwide with instruments, services, consumables, applications and expertise. The company has product categories which are Analytical Instruments & Supplies, Life Science, ad Clinical & Diagnostic Testing, out of which Life Science is market focused category. The company has a wide global presence across Europe, Asia-Pacific, North America, South Americas and Middle and Africa.

For Instances,

• In September 2021, Agilent Technologies, Inc. announced the signing of a worldwide distribution agreement with Visiopharm, enabling Agilent to co-market Visiopharm’s portfolio of CE-IVD marked artificial intelligence (AI)-driven precision pathology software and other products. This has increased the company’s product reach globally.